[摘要] 目的: 研究罗格列酮对2型糖尿病患者血清可溶性血管细胞粘附分子-1(sVCAM-1)水平的影响及其作用机制。 方法: 用酶联免疫吸附(ELISA)法测定2型糖尿病患者罗格列酮治疗前后血清sVCAM-1水平并分析其与肿瘤坏死因子(TNF-α)、HbA1C、空腹血糖(FBG)等的关系。 结果: 2型糖尿病患者服用罗格列酮后血清sVCAM-1水平下降(P<0.01);sVCAM-1与TNFα、HbA1C呈正相关。 结论: 罗格列酮能够降低2型糖尿病患者血清sVCAM-1水平，其机制可能与HbA1C生成减少、TNFα水平降低有关。

    [关键词] 2型糖尿病;可溶性血管细胞粘附分子-1;罗格列酮

    Effect of rosiglitazone on sVCAM-1in type2diabetic patients

    XU Mao-jin，YE Jiang-hong，ZOU Da-jin

    (Changhai Hospital，The Second Military Medical University，Shanghai 200433，China)

    Abstract:Objective:To study the effect of rosiglitazone on sVCAM-1(serum level of soluble vascular cell adhesion molecule-1)in type2diabetic patients.Methods:Serum level of sVCAM-1was measured by using ELISA before and after rosiglitazone intervention on type2diabetic patients and an analysis was made on the correlation between sVCAM-1and TNFα、HbA1C、FBG.Results:The serum levels of sVCAM-1decreased after rosiglitazone intervention(P<0.01);Results show that sVCAM-1is di-rectly proportional to TNFαand HbA1C.Conclusion:Rosiglitazone could obviously decrease serum level of sVCAM-1in type2dia-betic patients ......